Finanzen von Cullinan Therapeutics Inc (CGEM)CGEMCullinan Therapeutics Inc

Evaluating the bottom line, Cullinan Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -50.30%, provide a clear picture of how effectively CGEM converts its operational activities into shareholder value.

In the context of the broader market, CGEM competes directly with industry leaders such as ABUS and AKTS. With a market capitalization of $877.80M, it holds a significant position in the sector. When comparing efficiency, CGEM's gross margin of N/A stands against ABUS's 100.00% and AKTS's 100.00%. Such benchmarking helps identify whether Cullinan Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Cullinan Oncology has reported consistent net losses, with a net income of -49.661 million USD in Q1 2026 and a forward P/E ratio of 6.7385, indicating potential undervaluation despite ongoing losses.